AzTrials
AzTrials

Adnexal MassesR-IOTANCT07793201

Machine Learning Algorithms Incorporating Radiomic Ultrasound Features

An observational study of Adnexal Masses, run by Fondazione Policlinico Universitario Agostino Gemelli IRCCS at 1 site in Italy.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

Adnexal masses represent a frequent clinical finding and their preoperative characterization remains challenging. Accurate discrimination between benign and malignant adnexal masses is essential to optimize patient management, avoid unnecessary surgery, and ensure appropriate referral of patients with suspected… Read more about this study

Who is it for?
Ages 18 years and older, women only
Conditions the study is for
Adnexal Masses
How many people
12,000 participants
Where
1 siteItaly
Study dates
Sep 2026to Sep 2029
How long will I take part?
12 Months
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • Women only
  • No healthy volunteers
  • Adult, Older adult

Study population: Patients with adnexal masses

Who may be able to join

  • Patients with an adnexal mass identified at ultrasound examination who either undergo surgery within 6 months of the ultrasound or have at least 1 year of follow-up. This includes: the retrospective cohort recruited from IOTA centers, and the prospective cohort recruited from nonIOTA centers.
  • Age ≥ 18 years old
  • Availability of at least one grayscale digital ultrasound image clearly depicting the adnexal mass.
  • Signed written informed consent

Who cannot join

  • Patients without available digital ultrasound images.
  • Patients without an outcome (final histology or follow up at one year).
  • Absence of written informed consent

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Antonia Carla Testa, Professor contact

+390630156399

antoniacarla.testa@policlinicogemelli.it

Italy1 site
  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS

    Roma, 00168

    Antonia Carla Testa, Professor, +39 063015639

Other trials in Italy

About this study

Official title: Machine Learning Algorithms Incorporating Radiomic Ultrasound Features for Clinical Precision in Diagnosing Adnexal Tumors and Optimizing Patient Management: a Multicenter IOTA Study

Adnexal masses represent a frequent clinical finding and their preoperative characterization remains challenging. Accurate discrimination between benign and malignant adnexal masses is essential to optimize patient management, avoid unnecessary surgery, and ensure appropriate referral of patients with suspected malignancy to specialized centers.

This multicenter international observational study aims to evaluate the diagnostic performance and clinical utility of ultrasound-based machine learning (ML) models incorporating radiomic features for the characterization of adnexal masses. The study will develop and validate artificial intelligence (AI)-based models using ultrasound imaging data to support the preoperative classification of adnexal masses.

Read more

The primary objective of the study is to evaluate the ability of ultrasound-based ML models to distinguish between benign and malignant adnexal masses.

Secondary objectives include the evaluation of additional AI-based classification models among masses identified as malignant, including the discrimination between borderline tumors, primary invasive malignancies, and metastatic lesions. Furthermore, the study will assess the ability of AI models to differentiate primary epithelial ovarian carcinoma from non-epithelial ovarian malignancies among cases classified as primary ovarian cancer.

The clinical utility of the developed models will be assessed using decision curve analysis. In addition, a retrospective post hoc evaluation will be performed in an independent prospective external validation cohort to explore the potential clinical impact of an AI-based preoperative model for the management of adnexal masses. This evaluation will compare AI model outputs with actual clinical decisions made during routine care, without influencing patient management or altering the diagnostic and therapeutic pathway.

The post hoc clinical impact analysis will assess diagnostic concordance between AI predictions and clinicians' preoperative assessments, the potential proportion of avoidable surgical procedures according to AI model predictions, surgical and follow-up complications, and cost-effectiveness through comparison of healthcare resource utilization between standard clinical management and a reconstructed AI-supported scenario.

Patient-reported outcomes will also be evaluated, including patient satisfaction regarding diagnostic communication, clarity of information provided, and perceived quality of care within the standard clinical management pathway.

Overall, this study aims to investigate whether ultrasound-based AI models integrating radiomic features can improve the characterization of adnexal masses and provide clinically useful tools to support personalized and efficient patient management.

Read the detailed description

Epithelial ovarian cancer and other tubo-ovarian malignancies represent a major clinical challenge among gynecological cancers, particularly in developed countries, where they are associated with substantial morbidity and mortality. Despite advances in diagnosis and treatment, the prognosis of advanced tubo-ovarian cancer remains poor, with overall 5-year survival rates ranging approximately between 30% and 45%. Early and accurate characterization of adnexal masses is therefore essential to optimize clinical management, ensure appropriate referral of patients with suspected malignancy to specialized centers, and avoid unnecessary surgical procedures in patients with benign disease.

International scientific societies, including the European Society of Gynaecological Oncology (ESGO), International Society of Ultrasound in Obstetrics and Gynecology (ISUOG), International Ovarian Tumor Analysis (IOTA) group, and European Society of Gynaecological Endoscopy (ESGE), recommend ultrasound examination as the first-line imaging modality for the evaluation and risk stratification of adnexal masses. Expert ultrasound assessment and validated prediction models, such as the Assessment of Different NEoplasias in the adneXa (ADNEX) model developed by the IOTA group, have demonstrated high diagnostic accuracy for the discrimination between benign and malignant adnexal lesions and have shown the ability to further classify malignant masses according to different tumor categories.

However, ultrasound-based characterization of adnexal masses remains dependent on the availability of expertise and may be influenced by interobserver variability. The development of objective and reproducible diagnostic tools capable of extracting additional information from ultrasound images may therefore represent an important opportunity to improve diagnostic consistency and support clinical decision-making.

In recent years, radiomics has emerged as an innovative approach for the quantitative analysis of medical images. Radiomic techniques allow the extraction of high-dimensional imaging features that may capture subtle patterns and characteristics not readily identifiable through conventional visual interpretation. When combined with machine learning (ML) algorithms, radiomic features derived from ultrasound images may provide new opportunities for automated lesion characterization and improved prediction of tumor behavior.

Preliminary studies investigating ultrasound radiomics and artificial intelligence approaches in adnexal masses have shown promising results; however, currently available evidence is limited by small sample sizes, single-center designs, heterogeneous methodologies, and insufficient external validation. Large multicenter international studies are needed to evaluate the reproducibility, generalizability, and clinical applicability of AI-based approaches in this setting.

The present multicenter international IOTA study aims to develop and validate ultrasound-based machine learning models integrating radiomic features for the characterization of adnexal masses. The study will collect and analyze ultrasound imaging data from participating centers and will evaluate the ability of AI-based models to provide accurate and reproducible classification of adnexal lesions.

The primary objective of the study is to assess the performance of ultrasound-based machine learning models incorporating radiomic features in distinguishing benign from malignant adnexal masses.

Secondary objectives include the evaluation of additional AI-based models for the characterization of malignant adnexal masses, including the discrimination between borderline tumors, primary invasive malignancies, and metastatic lesions among masses classified as malignant by the primary model. Furthermore, the study aims to evaluate the ability of AI-based approaches to differentiate primary epithelial ovarian carcinoma from non-epithelial ovarian malignancies among lesions classified as primary ovarian cancer.

The study will also investigate the potential clinical utility of the developed models through decision curve analysis, evaluating the potential net benefit of AI-assisted prediction strategies across different clinical decision thresholds.

An independent prospective external validation cohort will be used to further evaluate the generalizability of the developed models and to explore their potential impact in a real-world clinical setting. This analysis will be performed retrospectively and post hoc, comparing AI model outputs with actual clinical decisions made during routine patient care. Importantly, AI predictions will not be available to clinicians and will not influence diagnostic pathways, treatment decisions, surgical planning, or patient management.

The retrospective clinical utility assessment will include evaluation of the agreement between AI predictions and clinicians' preoperative assessment of malignancy based on available clinical and imaging information. In addition, the study will explore the potential proportion of surgical procedures that could have been avoided according to AI model predictions, while maintaining patient safety. Surgical and follow-up outcomes, including intraoperative and postoperative complications and complications occurring during follow-up, will also be evaluated, including specific analyses of cases classified retrospectively as potentially unnecessary procedures.

A health economic evaluation will be performed to compare healthcare resource utilization and costs associated with standard clinical management with a reconstructed scenario based on AI model outputs. This analysis aims to explore the potential cost-effectiveness of AI-supported strategies for the management of adnexal masses.

Patient-reported outcomes will also be assessed to evaluate aspects related to the patient experience during standard clinical management, including satisfaction with diagnostic communication, clarity of information provided, and perceived quality of care.

Overall, this study aims to provide robust multicenter international evidence regarding the performance, reproducibility, and potential clinical utility of ultrasound-based machine learning models incorporating radiomic features for the evaluation of adnexal masses. The ultimate goal is to investigate whether AI-assisted approaches may contribute to a more standardized, accurate, and personalized diagnostic pathway while supporting appropriate allocation of healthcare resources.

Conditions
Adnexal Masses
Keywords
Adnexal masses, Ovarian cancer, Ultrasound, Radiomics, Ultrasonography, Artificial intelligence
Medical subject headings
Ovarian Neoplasms

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT07793201
Study groupRoleWhat they receive
Development CohortPatients with adnexal masses evaluated at participating centers with available ultrasound imaging data and reference diagnosis. Data from this cohort will be used for the development and internal validation of ultrasound-based machine learning models incorporating radiomic features.
External Validation CohortIndependent prospective cohort of patients with adnexal masses enrolled at participating centers. This cohort will be used for external validation of the developed ultrasound-based machine learning models and assessment of their performance and generalizability. AI model outputs will not influence clinical management.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Diagnostic performance of an ultrasound-based machine learning model for discrimination of benign and malignant adnexal masses

    Diagnostic performance of a machine learning model incorporating ultrasound radiomic features for distinguishing benign from malignant adnexal masses, assessed against the reference diagnosis. Performance will be evaluated using area under the receiver operating characteristic curve (AUC-ROC), accuracy, sensitivity, specificity, and calibration.

    Measured: At final diagnosis or completion of 1-year follow-up

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted28 Aug 2026
  2. Study startSep 2026 (estimated)
  3. Primary completionJan 2028 (estimated)
  4. Study completionSep 2029 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Cross-sectional
Enrolment
12,000 participants (estimated)
Target duration
12 Months
IDs, dates and publications
ClinicalTrials.gov ID
NCT07793201
Sponsor's protocol ID
27546
Other IDs
RF-2024-12379537
Acronym
R-IOTA
Status last verified
Jul 2026
First submitted
31 Jul 2026
Last updated
28 Aug 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

An observational study of Adnexal Masses, run by Fondazione Policlinico Universitario Agostino Gemelli IRCCS at 1 site in Italy.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 28 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Antonia Carla Testa, Professor (+390630156399, antoniacarla.testa@policlinicogemelli.it), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Diagnostic performance of an ultrasound-based machine learning model for discrimination of benign and malignant adnexal masses (time frame: At final diagnosis or completion of 1-year follow-up). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Aug 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in